Navigation Links
Actavis Extends Portfolio With Four New Products in the U.S.

MORRISTOWN, N.J., Feb. 27 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, has received approval on four new products from the U.S. Food & Drug Administration.

The four products include:

Phendimetrazine tartrate tablets, 35mg: the generic equivalent of Bontril(R) tablets by Valeant Pharmaceuticals, are indicated in the adjunct management of weight loss. Annual sales of Phendimetrazine tartrate tablets had annual sales of US$3.1 million for the 12 months ending December 2007 according to IMS Health data.

Buspirone tablets, 30mg: the generic equivalent of Bristol Myers Squibb's Buspar(R). Buspirone tablets, used in the treatment of anxiety disorders, had annual sales of US$15.4 million for the 12 months ending December 2007 according to IMS Health data.

Baclofen tablets: the generic equivalent of Lioresal(R) tablets by Novartis, will be available in 10mg and 20mg strengths. Baclofen tablets are used to relax muscles and relieve pain and discomfort associated with certain nerve disorders.

Benztropine Mesylate Tablets, 0.5mg, 1mg, 2mg: are the generic equivalent to Cogentin(R). Benztropine mesylate is an antidrykinetic, which reduces the symptoms of Parkinson's disease by improving muscle control and reducing stiffness. Annual sales of Benztropine mesylate were US$12.8 million for the 12 months ending December 2007 according to IMS Health data.

Commenting on the new approvals, Terry Fullem, Vice President of Marketing and Portfolio in the U.S. said:

"These approvals signify our commitment to provide our customers with a broad and expanding pipeline. We launched 19 products in the United States in 2007 and plan to increase that number in 2008. Actavis currently has over 70 pending applications at the FDA, including a growing list of first-to-file generic products. This momentum in our development pipeline will ensure that we continue to be on the forefront of bringing new generic products to market."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Confirms its Patent Challenge of Kings Avinza(R)
2. Actavis Launches Amlodipine Tablets in the U.S.
3. Actavis Launches Carvedilol Tablets in the U.S.
4. EMC Extends Innovation for VMware environments
5. The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida
6. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
7. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
8. Compuware Covisint Extends Commitment to Healthcare Industry with Acquisition of Hilgraeve, Inc.
9. A Little Regular Exercise Extends Mens Lives
10. Advanced Home Care Extends Its Use of Authentidates Inscrybe(TM) Healthcare Platform
11. OSHA Extends Comment Period for Lookback Review of Methylene Chloride Standard
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology: